Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 62
- Registration Number
- NCT00196846
- Locations
- 🇩🇪
Universitätsfrauenklinik, Rostock Universität, Rostock, Mecklenburg Vorpommern, Germany
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Metastatic Renal Cell Carcinoma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 40
- Registration Number
- NCT00203866
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 35
- Registration Number
- NCT00186121
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- Conditions
- Stage III Prostate CancerProstate AdenocarcinomaStage IV Prostate CancerProstate CarcinomaRecurrent Prostate Carcinoma
- Interventions
- Other: Pharmacological Study
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 112
- Registration Number
- NCT00170157
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
- Conditions
- Adenocarcinoma of the ProstateProstate Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT00165399
- Locations
- 🇺🇸
University of Massachusetts Memorial Medical Center-University Campus, Worcester, Massachusetts, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 177
- Registration Number
- NCT00114114
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- Conditions
- Stage III Prostate CancerRecurrent Prostate CarcinomaStage IIB Prostate CancerStage IIA Prostate CancerStage I Prostate Cancer
- Interventions
- Biological: Recombinant Fowlpox-PSA(L155)/TRICOM VaccineBiological: Recombinant Vaccinia-TRICOM VaccineBiological: Sargramostim
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00108732
- Locations
- 🇺🇸
Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 385
- Registration Number
- NCT00104715
- Locations
- 🇫🇷
Polyclinique du Parc, Cholet, France
🇫🇷Centre Regional Francois Baclesse, Caen, France
🇫🇷Centre Hospitalier General, Le Mans, France
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00002881
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Cancer Research UK
- Registration Number
- NCT00002460
- Locations
- 🇬🇧
Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇬🇧Royal Marsden NHS Trust, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.